Baroda BNP Paribas Health and Wellness Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
- September 16, 2026
- Posted by: Chaitanya Auti
- Category: Mutual Funds
Baroda BNP Paribas Health and Wellness Fund Direct Growth Plan had a NAV of ₹10.8138 as of 15 September 2026 and scheme AUM of ₹507 Cr. Its 1-year, 3-year and 5-year returns are 10.18%, 0% and 0% respectively, and the scheme is tagged as High Risk. Our view is that this is still a relatively young sector fund, so the short track record matters more than the missing long horizon history; the portfolio is concentrated in healthcare names, which can make outcomes more dependent on sector cycles.
The fund also sits at an expense ratio of 0.43% and is benchmarked against Nifty 50. For investors who are comfortable with sharp swings and want healthcare exposure, the mix of recent positive return and focused holdings may be worth understanding, but the limited history means it is better suited for measured expectations than for judging long-term consistency.
Quick facts
| Particular | Details |
|---|---|
| NAV | ₹10.8138 as of 15 Sep 2026 |
| AUM | ₹507 Cr |
| Expense Ratio | 0.43% |
| Launch Date | 27 Jun 2025 |
| Min SIP | ₹500 |
| Risk Category | High Risk |
| Benchmark | Nifty 50 |
| Fund Category | Equity |
| Exit Load | NIL upto 10% of units and 1% for remaining units on or before 1Y, Nil after 1Y |
| Fund Managers | Sanjay Chawla, Ankeet Pandya |
The fund is managed by Sanjay Chawla and Ankeet Pandya.
Source data date: as of 15 Sep 2026
Performance
| Period | Fund return | Benchmark return |
|---|---|---|
| 1M | -1.03% | -4.81% |
| 3M | 6.86% | -3.63% |
| 1Y | 10.18% | -8.27% |
| 3Y | Data not available | Data not available |
| 5Y | Data not available | Data not available |
Near term, the fund has held up better than the benchmark. The 1-month return is slightly negative, but it still declined less than the benchmark, while the 3-month and 1-year figures are clearly ahead of Nifty 50. That pattern suggests the fund has recently delivered a stronger healthcare-led rebound than the broader market.
At the same time, the longer record is not yet rich enough to judge consistency across a full market cycle. Since the scheme launched in June 2025, the available history is essentially a short live track record rather than a mature long-term series. That means the positive 1-year return is useful, but it should not be read as proof of durable outperformance.
The recent path also looks uneven rather than smooth. The fund has moved through periods of recovery and short pullbacks, which is consistent with a specialised equity strategy. For investors, that usually means the payoff can be meaningful when the sector is in favour, but the ride can still be choppy versus a broad market benchmark.
Source data date: as of 15 Sep 2026
Should you BUY or HOLD Baroda BNP Paribas Health and Wellness?
A fund’s past returns alone don’t tell you whether you should buy it today or continue holding it.
The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.
Already holding Baroda BNP Paribas Health and Wellness? Thinking of investing now?
Peer comparison
| Fund | 1Y return | 3Y return | 5Y return |
|---|---|---|---|
| Baroda BNP Paribas Health and Wellness Fund Direct Growth Plan | 10.18% | Data not available | Data not available |
| ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan | 69.8% | 36.32% | Data not available |
| Kotak Healthcare Fund Direct Growth Plan | 26.51% | Data not available | Data not available |
| Motilal Oswal Active Momentum Fund Direct Growth Plan | 25.46% | Data not available | Data not available |
| HDFC Pharma and Healthcare Fund Direct Growth Plan | 25.31% | Data not available | Data not available |
| PGIM India Healthcare Fund Direct Growth Plan | 23.52% | Data not available | Data not available |
This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639.
On the available 1-year figures, the fund trails the stronger peer returns in this set, especially the higher healthcare and thematic outcomes. Its own 1-year return is still positive, but the gap versus several peers shows that the recent run has been steadier than standout.
For longer horizons, only one peer has a usable 3-year figure, and that peer is far ahead at 36.32%. Against that backdrop, the fund’s lack of 3-year and 5-year history is an important limitation rather than a neutral detail. The short-term and longer-term peer picture therefore tell different stories: recent resilience is visible, but there is not enough vintage to compare mature compounding.
Source data date: as of 15 Sep 2026
Want to know more? Log in to Univest for more mutual fund insights.
Portfolio: where your money goes
| Holding | Sector | Weight |
|---|---|---|
| Sun Pharmaceutical Industries Limited | Healthcare | 9.01% |
| Divi’S Laboratories Limited | Healthcare | 8.01% |
| Torrent Pharmaceuticals Limited | Healthcare | 7.99% |
| Ipca Laboratories Limited | Healthcare | 6.23% |
| Lupin Limited | Healthcare | 5.99% |
| Laurus Labs Limited | Healthcare | 5.66% |
| Apollo Hospitals Enterprise Limited | Healthcare | 5.44% |
| Fortis Healthcare Limited | Healthcare | 4.5% |
| Astrazeneca Pharma India Limited | Healthcare | 3.56% |
| Glenmark Pharmaceuticals Limited | Healthcare | 3.42% |
The largest holding, Sun Pharmaceutical Industries Limited, carries a weight of 9.01%, so no single name is overwhelmingly dominant. The gap down to the tenth holding, Glenmark Pharmaceuticals Limited at 3.42%, is meaningful but not extreme, which suggests the portfolio still keeps several positions relevant.
The top 10 holdings together account for approximately 59.81% of the portfolio, and the scheme discloses 33 holdings in total. That combination points to moderate concentration: the fund is not built around one or two oversized bets, but the disclosed sleeve is still weighted heavily toward its largest names and may be more sensitive to healthcare-specific moves.
Because all 10 disclosed holdings are healthcare names, the portfolio likely has very clear sector focus. That can support stronger sector-led upside when sentiment is favourable, but it also means the fund may have less diversification across parts of the broader market than a multi-sector equity scheme.
To see all holdings, visit the Baroda BNP Paribas Health and Wellness Fund Direct Growth Plan page
Source data date: as of 15 Sep 2026
Who should invest
This fund suits investors who can tolerate High Risk and are comfortable with a specialised healthcare strategy rather than a broad market approach. The return pattern shows a positive 1-year result, but the absence of meaningful 3-year and 5-year history means the fund should be viewed more as a recent track record than as a full-cycle proof point.
It may fit an investment horizon long enough to absorb sector swings and wait for healthcare-led phases to play out. The main trade-off is straightforward: you get focused exposure to a healthcare-heavy portfolio, but you accept weaker diversification and a benchmark comparison that has been favourable only in the short run.
Tax and exit load
| Holding period | Tax rate | Description |
|---|---|---|
| Units held less than 1 year | 20% | Short-term capital gains tax |
| Units held more than 1 year | 12.5% | Long-term capital gains tax |
Exit load: NIL upto 10% of units and 1% for remaining units on or before 1Y. Nil after 1Y.
Source data date: as of 15 Sep 2026
Frequently asked questions
What is the current NAV of Baroda BNP Paribas Health and Wellness Fund Direct Growth Plan?
The current NAV is ₹10.8138 as of 15 September 2026.
What are the fund’s 1-year, 3-year and 5-year returns?
Its 1-year return is 10.18%, while the 3-year and 5-year returns are Data not available.
How has the fund performed versus Nifty 50?
It has done better than Nifty 50 over 1 month, 3 months and 1 year. The benchmark figures are -4.81%, -3.63% and -8.27% over those same periods.
How does it compare with the peer funds listed here?
Its 1-year return of 10.18% is below several peer figures in the comparison set, while the longer-term comparison is limited because the fund does not yet have 3-year or 5-year figures.
What is the minimum SIP amount?
The minimum SIP amount is ₹500.
Who manages the fund and what is the exit load?
The fund is managed by Sanjay Chawla and Ankeet Pandya. Exit load is NIL upto 10% of units and 1% for remaining units on or before 1Y, and nil after 1Y.
Bottom line
Baroda BNP Paribas Health and Wellness Fund Direct Growth Plan shows a better recent run than its benchmark, but the fund’s longer-horizon evidence is still limited because it launched in June 2025. Compared with the peer set, its 1-year return is modest, while the lack of 3-year and 5-year figures makes deeper compounding comparisons impossible. The portfolio is heavily focused on healthcare names, so investors are taking a clear sector view rather than a diversified equity stance. That makes the fund more suitable for investors who accept focused risk and shorter track record uncertainty.
Published on 16 September 2026 at 5:59 PM IST
Explore mutual funds with Univest
Review mutual fund data, compare performance and explore fund insights on Univest.
RIA disclosure
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.